Welcome to LookChem.com Sign In|Join Free
  • or
1-<3-(2-Hydroxyethoxy)phenyl>ethanon is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

126572-94-9

Post Buying Request

126572-94-9 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

126572-94-9 Usage

Physical State

Colorless to pale yellow liquid

Odor

Sweet, floral

Solubility

Soluble in alcohol and oils

Applications

Flavoring and fragrance ingredient in consumer products

Usage

Perfumes, soaps, and personal care products

Properties

Antimicrobial and antioxidant

Additional Applications

Cosmetic and pharmaceutical industries

Check Digit Verification of cas no

The CAS Registry Mumber 126572-94-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,2,6,5,7 and 2 respectively; the second part has 2 digits, 9 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 126572-94:
(8*1)+(7*2)+(6*6)+(5*5)+(4*7)+(3*2)+(2*9)+(1*4)=139
139 % 10 = 9
So 126572-94-9 is a valid CAS Registry Number.

126572-94-9Relevant academic research and scientific papers

PYRAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS

-

Page/Page column 87, (2018/09/21)

The present invention is directed to pyrazole derivatives, pharmaceutical compositions comprising the compounds and the use of the compounds or the compositions in the treatment of various diseases

Copper(ii)-catalyzed C-O coupling of aryl bromides with aliphatic diols: Synthesis of ethers, phenols, and benzo-fused cyclic ethers

Liu, Yajun,Park, Se Kyung,Xiao, Yan,Chae, Junghyun

supporting information, p. 4747 - 4753 (2014/06/24)

A highly efficient copper-catalyzed C-O cross-coupling reaction between aryl bromides and aliphatic diols has been developed employing a cheaper, more efficient, and easily removable copper(ii) catalyst. A broad range of aryl bromides were coupled with aliphatic diols of different lengths using 5 mol% CuCl2 and 3 equivalents of K2CO3 in the absence of any other ligands or solvents to afford the corresponding hydroxyalkyl aryl ethers in good to excellent yields. In this newly developed protocol, aliphatic diols have multilateral functions as coupling reactants, ligands, and solvents. The resulting hydroxyalkyl aryl ethers were further readily converted into the corresponding phenols, presenting a valuable alternative way to phenols from aryl bromides. Furthermore, it was demonstrated that they are useful intermediates for more advanced molecules such as benzofurans and benzo-fused cyclic ethers. This journal is

NITROGENOUS CYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME

-

, (2008/06/13)

The present invention provides a novel compound having a superior calcium antagonism, in particular, a neuron-selective calcium antagonism. Namely, it provides a compound represented by the following formula, a salt thereof or a hydrate of them. In the formula, Ar indicates an optionally substituted 5- to 14-membered aromatic ring etc.; the ring A indicates any one ring selected from a piperazine, a homopiperazine, a piperidine and the like; the ring B indicates an optionally substituted C3-14 hydrocarbon ring etc.; E indicates a single bond, a group represented by the formula -CO-, etc.; X indicates a single bond, an oxygen atom etc.; R1 indicates a hydrogen atom, a halogen atom, a hydroxyl group etc.; and D1, D2, W1 and W2 are the same as or different from each other and each represents a single bond or an optionally substituted C1-6 alkylene chain.

Aromatic compounds containing basic and acidic termini useful as fibrinogen receptor antagonists

-

, (2008/06/13)

This invention relates to novel compounds containing basic and acidic termini, pharmaceutical compositions containing such compounds, processes for preparing such compounds, and to methods of using these compounds, alone or in combination with other therapeutic agents, for the inhibition of platelet aggregation, as thrombolytics, and/or for the treatment of thromboembolic disorders.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 126572-94-9